Search PubMed⌕ Search

Biomedical subjects

B Meyer

Publications and source records attributed to B Meyer.

At least 163 records · Page 9Linked to original sources
PubMed1995

The scid mouse as an experimental model for the evaluation of anti-Pneumocystis carinii therapy.

The usefulness of scid mice bearing endogenous Pneumocystis carinii infection as a model for experimental chemotherapy was examined using standard compounds known to be effective against P. carinii. Trimethoprim/sulphamethoxazole was able to reduce pulmonary P. carinii cysts in a dose-dependent manner within the dose range studied (10/50 to 100/500 TMP/SMX mg/kg/d, bd, po, 5 days per week for 30 treatments). However, alterations in associated symptoms of infection (reduced body weight, increased lung weight, increased blood leucocytes and erythrocytes), was apparently not linearly dose-dependent. Blood and lung lavage fluid levels of sulphamethoxazole one hour post administration of trimethoprim/sulphamethoxazole was dose-dependent, but not linear with dose, and was apparently correlated to cyst reduction; trimethoprim was below the limit of detection at this time. Treatment of mice with 100/500 mg/kg/day trimethoprim/sulphamethoxazole required 2 weeks (bd for 10 days of treatment) before changes in indices of infection became significant. Pentamidine (20 mg/kg, sc, three times per week for 3 weeks) was nearly as effective as high-dose trimethoprim/sulphamethoxazole in reducing cysts, whereas lower doses were ineffective. Despite being unable to reduce pulmonary P. carinii infection, even low doses of pentamidine (6 or 2 mg/kg, sc, three times per week for 3 weeks) were able to reduce lung weights and blood leucocyte levels. This model of pulmonary P. carinii infections is amenable to chemotherapeutic intervention in an apparently dose-dependent fashion, and can be used to evaluate the capacity of compounds to eradicate P. carinii and resolve signs of infection.

Animals↗
PubMed1995

Isolation of Coxiella burnetii from heart valves of patients treated for Q fever endocarditis.

Coxiella burnetii was isolated from the valve material of two patients who underwent valvectomy because of progressive congestive heart failure due to endocarditis. In each case antibiotic therapy was administered for several months prior to valvectomy. Classical histopathological examination of the valves did not reveal an etiology. However, coxiella-like organisms were demonstrated in valvular material with Köster, Stamp, and Giemsa stains, and the organisms were grown in cell culture. Antibody titers were consistent with the diagnosis of chronic C. burnetii infection. This report illustrates the advantage of simple and fast staining techniques and cell culture for the demonstration and isolation of C. burnetii in the heart valve tissue of patients with Q fever endocarditis.

Antibodies, Bacterial↗
PubMed1995

Stereotactic puncture and lysis of spontaneous intracerebral hemorrhage using recombinant tissue-plasminogen activator.

We have tested a treatment protocol for intracerebral hemorrhage (ICH), consisting of stereotactic insertion of a catheter into the clot, hematoma lysis by the injection of a fibrinolytic agent, recombinant tissue-plasminogen activator (rt-PA), and closed system drainage of the liquefied clot. Fourteen patients underwent computed tomographically guided stereotactic hematoma puncture and silicone tube insertion within 72 hours of intracerebral hemorrhage. The majority (nine patients) suffered from ganglionic ICH, and the size of the hematoma ranged between 3 x 3 x 4 cm and 7 x 7 x 4 cm (mean, 5.2 x 4 x 3.6 cm). All patients had major neurological deficits with or without an impaired level of consciousness, but without signs of transtentorial herniation. The initial, then daily, dose (in milligrams) of rt-PA administered via the silicone tube equalled the maximal diameter (in centimeters) of the original and remaining clot as measured initially, then daily, by computed tomographic scan. The number of rt-PA injections was four in one patient, three in eight patients, two in four patients, and one in one patient, and the total dose of rt-PA required ranged from 5 to 16 mg (mean, 9.9 mg). After rt-PA injection, the tubing was clamped for 2 hours and then opened to drain spontaneously through a closed system against 0 cm of pressure. At follow-up 6.6 months (mean) after treatment (ranging from 3 to 13 months) and according to the Glasgow outcome score, one patient was Grade V, four were Grade IV, five were Grade III, two were Grade II, and two had died.(ABSTRACT TRUNCATED AT 250 WORDS)

Adult↗
PubMed1995

Clinical results for the DIGISONIC multichannel cochlear implant.

The DIGISONIC is a digitized 15-channel cochlear implant. A special version of this implant has been designed for use in the totally obstructed cochlea. This device has 10 separate electrodes that may be inserted, one by one, into 10 different holes drilled in the bony cochlea. The device's 128-point Fast Fourier Transform analysis supplies the patient with the entire set of the sound information between 100 and 7800 Hz. The stimulation rhythm is set at a programmable frequency among 125 and 400 Hz or slaved to the fundamental pitch frequency. The flexibility of the microprocessor makes it possible to select the best width and mean value of each frequency band for each electrode. Many speech-coding strategies may be easily programmed as a function of scientific desiderata. The authors present clinical results for the first 28 patients they treated with this cochlear implant.

Adolescent↗
PubMed1995

Speech coding strategies of the digisonic fully digitized cochlear implant.

The Digisonic is a fully digitized cochlear implant. Because of its articulated array, its 15 electrodes can be inserted in the cochlea. Each electrode is recessed in a special silastic compartment of the array and has a very large stimulation area thanks to its large microrelief surface area. The small volume of its implanted receiver (flat cylinder diam 29 mm, 6.9 mm thick) allows it to be placed in 2-year-old children. The 128 point FFT of this device supply the patient with a full set of sound information between 64 and 7800 Hz. Electrode stimulation mode is sequential and stimulation rhythm is programmable. Electric crosstalk is decreased by the shape of the electrode array, and optionally by special programming of the neighboring electrodes. The speech therapist may select the width and peak value of each frequency band handled by each functional electrode. Because the versatility of this digitized emitter, many speech coding strategies can be easily programmed as a function of electrode responses or particular scientific considerations. A special version of this device, consisting of 10 separate electrodes, has been designed for use in patients with total obstruction of the cochlea. These insulated wires may be inserted one by one in the inner ear in 10 different recesses gently drilled in the bony cochlea. This device was placed in 46 patients between 1992 and 1994, including 8 young children (aged 2-9 years, mean 5 years) and 9 patients with total cochlear obstruction.

Child↗
PubMed1995

Association of venous and true arteriovenous malformation: a rare entity among mixed vascular malformations of the brain. Case report.

In this article the authors report the case of a mixed cerebrovascular malformation in which a true arteriovenous malformation (AVM), harboring a nidus, is associated with a venous malformation that serves as the draining vein for the nidus. Despite the authors' preoperative rationale for exclusive extirpation of the AVM, an inadvertent injury and the obliteration of the venous malformation generated delayed postoperative neurological deterioration, which could clearly be attributed to venous hemorrhagic infarction. Because this is only the second instance of this type of mixed vascular malformation of the brain reported, which also underscores the concept of nonsurgical treatment of venous malformations, the authors discuss the diverse literature regarding mixed vascular malformations and the treatment of venous malformations.

Abnormalities, Multiple↗
PubMed1995

[Signal processing and clinical results with the French cochlear implant Digisonic].

The Digisonic is a totally digitised multichannel cochlear implant remarkable for the versatility of its sound signal processing. Owing to its flexible and articulated array, its 15 electrodes are usually introduced in the scala tympani. A special version of this device has been designed to be used in case of total obstructed cochlea. It consists of separated electrodes which may be inserted one by one in the inner ear in different holes gently drilled in the bony cochlea. The possibilities of the microprocessor allow the speech therapist to carefully select the best width and mean value of each frequency band respectively devoted to each functional electrode. These parameters may be adapted to progressively improve the patient's hearing performances as a function of his phonemic discrimination and or the number and the tonotopy of his functional electrodes. Moreover, owing to the versatility of this digitised emitter a lot of speech coding strategies may be easily programmed as a function of eventual desiderata. Its high miniaturisation leads this implant to be particularly useful for young children. Results of our 38 first implanted patients (age 2-74; mean 42) including 7 cases of totally obstructed cochlea are reported.

Adolescent↗
PubMed1995

[Cochlear implants and total cochlear obstruction].

Total cochlea obstruction is not a contraindication for cochlear implant. We report our experience owing to the single channel cochlear implant Monosonic (9 cases), partial insertion of the electrodes-array (3 cases: 1 Digisonic and 2 minisystem) and, more recently the separate electrodes version of the Digisonic (6 cases). This new device is encouraging because it supplies 2/5 patients with telephone use.

Adolescent↗
PubMed1995

[Evaluation protocol of cochlear implants in children under 5 years of age].

Special tests are necessary to assess the cochlear implant efficacy on a prelingually deaf child implanted before age 5 y. We propose to quantify comportment, comprehension, auditory perception and expression as percentage of a same age normally hearing child's scores. The particular items are detailed.

Age Factors↗
PubMed1995

Antioxidative properties of alcoholic extracts from Fraxinus excelsior, Populus tremula and Solidago virgaurea.

Aqueous-ethanolic extracts from Fraxinus excelsior, Populus tremula and Solidago virgaurea inhibit biochemical model reactions representing inflammatory situations to various extents. These model reactions include xanthine oxidase, diaphorase in the presence of the autoxidizable quinone juglone, lipoxygenase and photodynamic reactions driven by riboflavin or rose bengal. The tested extracts are the components of the phytomedicine Phytodolor N (abbreviated as PD) which possesses antipyretic, analgesic, antiinflammatory and antirheumatic activity. Since several reactive oxygen species produced by the mentioned model systems are also involved in inflammatory processes, the beneficial activities of the complete drug may at least in part be due to the reported antioxidative functions of the individual components.

Animals↗
PubMed1995

Correlation of bone marrow minimal residual disease and apparent isolated extramedullary relapse in childhood acute lymphoblastic leukaemia.

We have used a polymerase chain reaction (PCR) technique capable of detecting one leukaemic cell in 10(5) normal cells to monitor minimal residual disease (MRD) in a retrospective study of childhood ALL. We were particularly interested in comparing MRD findings in patients in long-term remission, bone marrow relapse and apparent isolated extramedullary relapse (EMR). Archival slides were initially studied from 21 patients. However, on subsequent analysis, only 15 patients were informative at the molecular level. All seven patients with EMR had evidence of MRD in the bone marrow at the time of relapse. Five of the seven also had evidence of bone marrow MRD prior to EMR. In one of the seven patients, MRD was not detected in a bone marrow sample studied 5 months prior to EMR. The remaining EMR patient was not studied prior to EMR. Of five patients who remained in long-term remission (mean 144 months), three did not have detectable MRD at the end of induction therapy (2 months) and all five were MRD-negative at the end of treatment (36 months). This contrasts with the three patients who relapsed in the bone marrow at 8, 15 and 88 months post-treatment and who had evidence of MRD at the end of therapy.

Bone Marrow↗
PubMed1995

Intestinal mucosal mononuclear cell chimaerism after sex-mismatched allogeneic bone marrow transplantation.

The contribution of haemopoietic cell chimaerism to the pathogenesis of GVHD after BMT is unclear. This report raises the possibility that donor lymphocyte-recipient macrophage chimaerism may occur shortly after allogeneic marrow engraftment and hence might contribute to the development of GVHD. Immunohistological studies of intestinal mucosa in an allogeneic BMT patient, who did not engraft, revealed an almost complete absence of lymphocytes 30 days after transplant, but preservation of mucosal macrophage numbers. Subsequently, combined immunohistology-Y chromosome in situ hybridization studies were performed in two female BMT recipients of male donor marrow. These studies revealed that between 25 and 40% of macrophages and between 25 and 40% of T lymphocytes were of donor origin during the first 6 months after transplant. In conclusion, whilst the immunohistological studies of intestinal mucosa from a patient who failed to engraft suggest that donor lymphocyte-recipient macrophage ('split') chimaerism may occur shortly after marrow engraftment, the subsequent in situ hybridization studies revealed 'mixed' chimaerism in the two sex-mismatched BMT recipients.

Adult↗
PubMed1995

Bioequivalence evaluation of two different oral formulations of loperamide (Diarex Lactab vs Imodium capsules).

Twenty-four healthy male volunteers were treated with two different oral formulations of loperamide according to a randomized two-way cross-over design. The test preparation was Diarex Lactab (Mepha), the reference preparation Imodium 2 mg capsules. Divided in two periods the volunteers received single 8 x 2 mg (= 16mg) doses of the test and reference formulation, respectively. Blood samples were taken immediately prior to each administration and at 14 points within 60 h after the dose. A wash-out period of 1 week was interpaused between successive drug doses. The plasma concentration of the pharmacologically active compound, loperamide, was determined by HPLC with electrochemical detection. The calibration function was linear in the range 0-10.0 ng/ml. A lower limit of quantification of 0.2 ng/ml was established. The pharmacokinetic parameters Cmax and tmax were obtained directly from plasma data. The elimination constant was estimated by log-linear regression of the measured concentrations in the terminal phase. AUC was calculated by the trapezoidal rule and extrapolated to infinity. The following mean values were obtained after intake of 16 mg loperamide as film coated tablets: AUC0 infinity 62.04 ngh/ml, Cmax 3.35 ng/ml, tmax 4.08 h, t1/2 19.66 h and after administration of the capsules: AUC0 infinity 66.56 ngh/ml, Cmax 3.98 ng/ml, tmax 4.38 h, t1/2 18.43 h. The pharmacokinetic parameters AUC0 infinity and Cmax were tested for bioequivalence parametrically (two one-sided t-tests) after logarithmic transformation of data. Differences of tmax were evaluated non-parametrically. The preparations were found to be bioequivalent and, therefore, interchangeable.

Administration, Oral↗